TKIs Appear Safe in Patients With Chronic Myeloid Leukemia, CKD
the ONA take:
Tyrosine kinase inhibitors (TKIs) seem safe in patients with chronic myeloid leukemia (CML) in chronic-phase and chronic kidney disease, a recent study published online ahead of print in the journal Cancer has shown.
For the study, researchers investigated the incidence of acute injury and chronic kidney disease in 468 patients with newly diagnosed chronic-phase CML who were treated with imatinib, dasatinib, or nilotinib.
Results showed that 4% of patients experienced TKI-associated acute kidney injury. Researchers found that imatinib was associated with an increased incidence of acute kidney injury compared with dasatinib and nilotinib.
The study also demonstrated that 14% of patients developed chronic kidney disease while receiving TKI treatment. Of those, 84% were receiving imatinib. However, in patients with a history of chronic kidney disease, imatinib did not cause a significant decline in glomerular filtration rate.
"The administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted," Musa Yilmaz, M.D., from the Baylor College of Medicine in Houston, TX, and colleagues wrote.
Tyrosine kinase inhibitors seem safe in patients with chronic myeloid leukemia in chronic-phase and chronic kidney disease.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|